While in cancer immunotherapy the blockade of CD73 seems a promising strategy (84), the systemic usage of CD73 to dampen inflammation is hampered by vasodilation and subsequent decrease in blood pressure in response to adenosine receptor engagement in the vasculature. The gene discussed is NT5E; the disease is cancer.